Generic Name and Formulations:
Interferon beta-1b 0.3mg; per vial; pwd for SC inj after reconstitution; contains albumin (human), mannitol; preservative-free.
Company:
Bayer Healthcare Pharmaceuticals Inc.
To reduce the frequency of clinical exacerbations in patients with relapsing forms of multiple sclerosis (MS), and in those who have experienced a first clinical episode and have MRI features consistent with MS.
≥18yrs: initially 0.0625mg (0.25mL) SC every other day; increase over 6 weeks to 0.25mg (1mL) SC every other day.
<18yrs: not established.
Hypersensitivity to E. coli-derived products.
Myelosuppression. Monitor for worsening CHF, depression, elevated transaminases, jaundice: may need to discontinue therapy. Obtain hemoglobin, CBC, differential, platelets, blood chemistries; liver function (at 1, 3, and 6 months then periodically). Pregnancy (Cat.C): may be abortifacient; consider discontinuing drug. Nursing mothers: not recommended.
Monitor with myelosuppressants.
Inj site reactions/necrosis, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia; depression, suicide, hepatic failure, worsening CHF, anaphylaxis, possible seizures.
Single-use vials (w. prefilled diluent syringes)—14